Bio-Path Holdings, Inc. (NASDAQ: BPTH) is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systematically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company’s initial focus is on cancer, and its lead candidate, BP1001, is in phase II study for blood cancers. Bio- Path’s second drug candidate is ready for the clinic where it will be evaluated in lymphoma and solid tumors. For more information, please visit the company’s website at www.biopathholdings.com.